Bot Detector
IJPC Seal
Download FREE Sample Issue or Article
LEARN MORE
Subscribe Today
A subscription to IJPC provides on-line access to full-text, full-color, printable PDF copies of your subscribed issues, individual articles, and purchased archives.

Naratriptan HCl in Extemporaneously Compounded Oral Suspensions

Author(s):  Zhang Yanping, Trissel Lawrence A, Fox Janet L

Issue:  Jan/Feb 2000 - Compounding for Pain Management
View All Articles in Issue

Page(s):  69-71

Naratriptan HCl in Extemporaneously Compounded Oral Suspensions Page 1
Naratriptan HCl in Extemporaneously Compounded Oral Suspensions Page 2
Naratriptan HCl in Extemporaneously Compounded Oral Suspensions Page 3

Download in electronic PDF format for $75

Abstract:  The purpose of this study was to determine the pharmaceutical acceptability and chemical stability of naratriptan hydrochloride in three extemporaneously compounded suspension formulations.

The naratriptan-hydrochloride oral suspensions were prepared from 2.5-mg commercial tablets yielding a nominal naratriptan concentration of 0.5 mg/mL. The suspension vehicles selected for testing were Syrpalta,® an equal-parts mixture of Ora-Plus™ and Ora-Sweet,™ and an equal-parts mixture of Ora-Plus and Ora-Sweet SF.™ The tablets were crushed and thoroughly triturated to a fine powder using a porcelain mortar and pestle. The powder was incorporated into a portion of the Syrpalta or Ora-Plus suspension vehicle and mixed until homogeneous. The mixtures were then brought to volume with Syrpalta, Ora-Sweet or Ora-Sweet SF, as appropriate. The suspensions were packaged in amber, plastic, screw-cap prescription bottles and stored at 23°C for seven days and 4°C for 90 days.

An adequate suspension was never achieved in Syrpalta. The crushed-tablet powder did not produce a uniformly dispersed mixture and exhibited clumping and a high rate of sedimentation. A distinct layer of the solid tablet material settled immediately after shaking. Over the next four hours, a densely packed, yellow, caked layer formed at the bottom of the containers, making resuspension difficult. During storage, the caking became worse. Chemical analysis was not performed.

The Ora-Plus and Ora-Sweet or Ora-Sweet SF suspensions had a slight greenish cast and were resuspended without difficulty by shaking for approximately ten seconds, yielding easily poured and homogeneous mixtures throughout the study. Visible settling and layering did not begin for four hours with the Ora-Sweet suspension and 24 hours for the Ora-Sweet SF suspension. High-pressure liquid chromatographic analysis found that the naratriptan concentration in both suspensionvehicle combinations exhibited little or no loss for seven days at 23°C and 90 days at 4°C. At least 96% of the initial concentration remained at all time points.

Naratriptan hydrochloride extemporaneously prepared as oral suspensions from tablets in equal-parts mixtures of Ora- Plus suspension vehicle with Ora-Sweet and with Ora-Sweet SF syrups was pharmaceutically acceptable and chemically stable for at least seven days at 23°C and 90 days at 4°C. Syrpalta was unacceptable for use as a vehicle for naratriptan hydrochloride suspensions prepared from tablets.

Related Keywords: chemical stability, high-pressure liquid chromatography, naratriptan, oral suspension, Syrpalta, tablets

Related Categories: PEER-REVIEWED, STABILITIES, COMPATIBILITIES

Printer-Friendly Version



Related Articles from IJPC
Title/Author
(Click for Abstract / Details / Purchase)
Issue/​Page
View/Buy
Naratriptan HCl in Extemporaneously Compounded Oral Suspensions
Zhang Yanping
, Trissel Lawrence A, Fox Janet L
Jan/Feb 2000
Pg. 69-71

Stability of an Oral Liquid Dosage Form of Trovafloxacin Mesylate and Its Quantitation in Tablets Using High-Performance Liquid Chromatography
Gupta Vishnu D
May/Jun 2000
Pg. 233-235

Quantitation of Testosterone in Suspension using High Performance Liquid Chromatography
Gupta Vishnu D
May/Jun 1999
Pg. 239-240

Naratriptan Hydrochloride 0.5-mg/mL Oral Liquid
Allen Loyd V Jr
Jan/Feb 2006
Pg. 66

Stability of Extemporaneously Prepared Hydroxycarbamide Oral Suspensions
Kabiche Djamila
, Balde Issa-Bella, Majoul Elyes, Kabiche Sofiane, Bourguignon Elodie, Fontan Jean-Eudes, Cisternino Salvatore, Schlatter Joel
Mar/Apr 2017
Pg. 160-163

Physicochemical and Microbiological Stability of Extemporaneously Compounded Hydrocortisone Oral Suspensions in PCCA Base, SuspendIt
Pramar Yashoda V
, Mandal Tarun K, Bostanian Levon A, Kader Cyndy, Morris Tommy C, Graves Richard A
Sep/Oct 2021
Pg. 431-439

Compounding in the Pharmacy Curriculum: Beyond the Basics
Hinkle Amanda R
, Newton Gail D
May/Jun 2004
Pg. 181-185

Temozolomide Stability in Extemporaneously Compounded Oral Suspensions
Trissel Lawrence A
, Zhang Yanping, Koontz Susannah E
Sep/Oct 2006
Pg. 396-399

Physical and Chemical Stability of Budesonide Mucoadhesive Oral Suspensions (MucoLox)
Ip Kendice
, Carvalho Maria, Shan Ashley, Banov Daniel
Jul/Aug 2017
Pg. 322-329

Quality-Control Analytical Methods: High-Performance Liquid Chromatography
Kupiec Thomas C
May/Jun 2004
Pg. 223-227

Stability of Allopurinol Suspension Compounded from Tablets
Alexander Kenneth S
, Davar Nipun, Parker Gordon A
Mar/Apr 1997
Pg. 128-131

Preparation and Stability Evaluation of Extemporaneous Oral Suspension of Valsartan Using Commercially Available Tablets
Zaid Abdel Naser
, Assali Mohyeddin, Qaddomi Aiman, Ghanem Mashhour, Zaaror Yara Abu
Mar/Apr 2014
Pg. 169-174

Stability Issues for Compounding Extemporaneously Prepared Oral Formulations for Pediatric Patients
Schotik Debora
Jan/Feb 2001
Pg. 9-12

Oral Liquid Vehicles, Featured Excipient:
Allen Loyd V Jr
Jan/Feb 2001
Pg. 65-67

Women's Oral Health: Is There a Hormonal Link?
Preckshot John
Jan/Feb 2004
Pg. 10-14

Quality Control and Physical and Chemical Stability of Hydrocortisone Oral Suspension: An Interlaboratory Study
Santoveña A
, Llabrés M, Fariña JB
Sep/Oct 2010
Pg. 430-435

Formulation Development and Stability Testing of Extemporaneous Suspension Prepared From Dapsone Tablets
Kaila Nitin
, El-Ries Mohamed, Riga A, Alexander Kenneth S, Dollimore D
May/Jun 2003
Pg. 233-239

Development of Extemporaneously Compounded Aripiprazole Oral Suspensions for Use in Children
Pramann Lance A
, Davidow Lawrence W, van Haandel Leon, Funk Ryan S
May/Jun 2016
Pg. 257-261

Stability of an Alcohol-free, Dye-free Hydrocortisone (2 mg/mL) Compounded Oral Suspension
Manchanda Arushi
, Laracy Melissa, Savji Taslim, Bogner Robin H
Jan/Feb 2018
Pg. 66-75

Quantitation of Testosterone-Cypionate-in-Oil Injection using High Performance Liquid Chromatography
Gupta Vishnu D
, Pramar Y
Jul/Aug 1999
Pg. 314-315

Return to Top